The maturing but highly lucrative market for MS DMTs continues to fragment as...
The maturing but highly lucrative market for MS DMTs continues to fragment as new entrants propel ongoing shifts in a complicated treatment algorithm. Roche/Genentech’s Ocrevus has intensif...
Market Outlook In the EU5, access to disease-modifying therapies (DMT
Market Outlook In the EU5, access to disease-modifying therapies (DMT...
With more than a dozen disease-modifying therapies (DMTs) available to treat...
With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the tr......
Market Overview In a landmark FDA ruling in March 2017, Ocrevus became the...
Market Overview In a landmark FDA ruling in March 2017, Ocrevus became the first disease-modifying therapy (...
This report is available to find out more click the link and fill out the form to get more details.
This report is available to find out more click the link and fill out the form to get more details.
This report is available to find out more click the link and fill out the form to get more details.
This report is available to find out more click the link and fill out the form to get more details.
This report is available to find out more click the link and fill out the form to get more details.
This report is available to find out more click the link and fill out the form to get more details.
Market Overview Ocrevus is the latest disease-modifying therapy (DMT) to...
Market Overview Ocrevus is the latest disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multipl...
A large array of clinically unique disease-modifying therapies (DMTs) is...
A large array of clinically unique disease-modifying therapies (DMTs) is approved for the treatment of multiple sclerosis (...
Market Outlook An increasing number of clinically unique disease-modifying...
Market Outlook An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the tre......
The dynamic multiple sclerosis (MS) market in the United States features more...
The dynamic multiple sclerosis (MS) market in the United States features more than a dozen high-cost branded (and one generic) disease-modifying therapies (...
In a landmark FDA ruling, Ocrevus became the first DMT approved for the...
In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of ...
Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the...
Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (...
With its launch in August 2016, Zinbryta became the 14thdisease-modifying...
With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple scl......
The maturing but highly lucrative market for MSDMTs continues to...
The maturing but highly lucrative market for MSDMTs continues to......
With the availability of over a dozen disease-modifying therapies (DMTs) to...
With the availability of over a dozen disease-modifying therapies (DMTs) to treat multiple sclerosis (MS), the treatment journey for MS...
In a landmark FDA ruling, Ocrevus became the first DMT approved for the...
In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of ...
Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment...
Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (...
With its launch in August 2016, Zinbryta became the 14th disease-modifying...
With its launch in August 2016, Zinbryta became the 14th disease-modifying therapy (DMT) approved to treat relapsing forms of multiple sc......
Multiple Sclerosis | Emerging Therapies | Zinbryta | US is a three-wave series...
Multiple Sclerosis | Emerging Therapies | Zinbryta | US is a three-wave series that tracks the introduction of Zinbryta for the treatment of multiple sclerosis (MS). The series is based on primar......
